UT San Antonio has been given a $38biin ARPA-H grant to study the health benefit effects o

Well SupportedHigh doses of rapamycin (e.g., 20mg weekly) are immunosuppressive and potentially interfere with vaccine response.

Partially SupportedSemaglutide reduces cardiovascular events based on post-market data, in addition to its use for diabetes and weight loss.

Partially SupportedDapagliflozin is a diabetes drug that improves metabolic health and lowers cardiovascular risk by increasing sugar excretion in urine.

Partially SupportedUT San Antonio received a $38 billion ARPA-H grant to study the health benefits of rapamycin, dapagliflozin, and semaglutide in humans.